Press releases

ORYZON to attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-29

ORYZON to provide corporate progress updates at several events in May-June

ORYZON reports financial results and corporate update for quarter ended March 31, 2025

ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

ORYZON Raises €30 Million in Capital Increase

ORYZON continues to strengthen its patent portfolio for vafidemstat

ORYZON announces first patient dosed in NCI-sponsored Phase I/II clinical trial of iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

ORYZON to provide corporate progress updates at several events in March-April

Oryzon announces publication of study on Phelan-McDermid Syndrome (PMS) patients, a form of autism, paving the way for a novel personalized medicine approach with vafidemstat

Oryzon defines Phase III Trial endpoints for Agitation and Aggression in BPD with input from new Clinical Advisory Board